GlassScriptPhysician profile
Muhammad A Imran
NPI 1568692820
$2,961.96
in general payments reported to CMS, 2019-2025
26 companies · $863 in 2025
The $863 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $36.11 · 2021: $181 · 2022: $493 · 2023: $914 · 2024: $371 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.54 |
| Education | $177.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $530.20 | 2022-2025 | |
| Glaxosmithkline, LLC. | $348.89 | 2021-2025 | Benlysta, Nucala, Trelegy Ellipta |
| Amgen INC. | $295.52 | 2020-2025 | Otezla, Enbrel, Krystexxa |
| Regeneron Healthcare Solutions, INC. | $245.98 | 2021-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $208.99 | 2022-2025 | Acthar |
| Janssen Biotech, INC. | $165.29 | 2022-2025 | Tremfya, Remicade, Simponi |
| Horizon Therapeutics Plc | $161.77 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $147.56 | 2021-2025 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $124.35 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $121.78 | 2023-2025 | Saphnelo, Airsupra, Tezspire |
| Ucb, INC. | $79.06 | 2025 | Bimzelx |
| Ars Pharmaceuticals Operations, INC. | $78.44 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $66.87 | 2019-2024 | |
| Pfizer INC. | $63.11 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $60.09 | 2025 | Purified Cortrophin Gel |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $50.18 | 2023-2024 | Ayvakit |
| Optinose US, INC. | $43.14 | 2025 | |
| Genentech USA, INC. | $25.66 | 2019 | |
| Jubilant Hollisterstier LLC | $24.43 | 2023 | |
| Cardiovascular Systems INC. | $22.31 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.71 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.11 | 2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.99 | 2019 | |
| Galderma Laboratories, L.P. | $13.86 | 2024 | |
| Depuy Synthes Sales INC. | $13.75 | 2023 | Orthovisc, Monovisc |
| Cumberland Pharmaceuticals, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Imran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.